Innova Captab Limited Cash Flow Conversion Efficiency
Innova Captab Limited cash flow conversion efficiency. Based on the latest financial reports, Innova Captab Limited (INNOVACAP) has a cash flow conversion efficiency ratio of 0.029x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs297.19 Million ≈ $3.21 Million USD) by net assets (Rs10.21 Billion ≈ $110.43 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Innova Captab Limited (2018–2026)
Cash flow conversion efficiency of Innova Captab Limited from 2018 to 2026. This chart illustrates how Innova Captab Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Innova Captab Limited (INNOVACAP) stock price for real-time trading data and today's change.
Innova Captab Limited Cash Flow Conversion Ratio Explained
Innova Captab Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Innova Captab Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Innova Captab Limited ranked by their cash flow conversion efficiency. Also see Innova Captab Limited market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tiptree Inc
NASDAQ:TIPT
|
0.000x |
|
Aura Biosciences Inc
NASDAQ:AURA
|
-0.279x |
|
Guizhou Sanli Pharmaceutical Co Ltd
SHG:603439
|
0.021x |
|
Jiangsu Olive Sensors High-Tech Co Ltd
SHE:300507
|
-0.025x |
|
SLR Investment Corp
NASDAQ:SLRC
|
0.017x |
|
Mega First Corporation Bhd
KLSE:3069
|
0.050x |
|
Hana Materials Inc
KQ:166090
|
0.064x |
|
Northern Data AG
XETRA:NB2
|
-0.021x |
Annual Cash Flow Conversion Efficiency for Innova Captab Limited (2018–2026)
The table below shows the annual cash flow conversion efficiency of Innova Captab Limited from 2018 to 2026. Review Innova Captab Limited free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs10.91 Billion ≈ $117.97 Million |
Rs1.03 Billion ≈ $11.11 Million |
0.094x | +41.47% |
| 2025-03-31 | Rs9.59 Billion ≈ $103.76 Million |
Rs638.44 Million ≈ $6.90 Million |
0.067x | -62.22% |
| 2024-03-31 | Rs8.31 Billion ≈ $89.86 Million |
Rs1.46 Billion ≈ $15.83 Million |
0.176x | -14.57% |
| 2023-03-31 | Rs3.26 Billion ≈ $35.21 Million |
Rs671.24 Million ≈ $7.26 Million |
0.206x | -26.98% |
| 2022-03-31 | Rs2.09 Billion ≈ $22.56 Million |
Rs588.98 Million ≈ $6.37 Million |
0.282x | +7.15% |
| 2021-03-31 | Rs1.45 Billion ≈ $15.66 Million |
Rs381.60 Million ≈ $4.13 Million |
0.263x | +224.86% |
| 2020-03-31 | Rs3.80 Billion ≈ $41.06 Million |
Rs307.97 Million ≈ $3.33 Million |
0.081x | -86.89% |
| 2019-03-31 | Rs305.11 Million ≈ $3.30 Million |
Rs188.72 Million ≈ $2.04 Million |
0.619x | +138.16% |
| 2018-03-31 | Rs626.18 Million ≈ $6.77 Million |
Rs162.62 Million ≈ $1.76 Million |
0.260x | -- |
About Innova Captab Limited
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs and pharmaceutical products in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cepha… Read more